1. Home
  2. TYRA vs GRC Comparison

TYRA vs GRC Comparison

Compare TYRA & GRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

HOLD

Current Price

$25.95

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Gorman-Rupp Company (The)

GRC

Gorman-Rupp Company (The)

HOLD

Current Price

$78.85

Market Cap

2.1B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
TYRA
GRC
Founded
2018
1933
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Fluid Controls
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.1B
IPO Year
2021
1994

Fundamental Metrics

Financial Performance
Metric
TYRA
GRC
Price
$25.95
$78.85
Analyst Decision
Strong Buy
Analyst Count
11
0
Target Price
$47.50
N/A
AVG Volume (30 Days)
621.4K
173.4K
Earning Date
05-06-2026
04-23-2026
Dividend Yield
N/A
1.04%
EPS Growth
N/A
32.03
EPS
N/A
1.41
Revenue
N/A
$682,389,000.00
Revenue This Year
N/A
$6.62
Revenue Next Year
N/A
$4.66
P/E Ratio
N/A
$57.20
Revenue Growth
N/A
3.44
52 Week Low
$9.96
$41.02
52 Week High
$40.65
$92.78

Technical Indicators

Market Signals
Indicator
TYRA
GRC
Relative Strength Index (RSI) 37.80 41.61
Support Level $24.77 $75.97
Resistance Level $32.82 $79.95
Average True Range (ATR) 1.67 2.95
MACD -0.34 -0.39
Stochastic Oscillator 14.97 6.89

Price Performance

Historical Comparison
TYRA
GRC

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

About GRC Gorman-Rupp Company (The)

Gorman-Rupp Co designs, manufactures, and globally sells pumps & pump systems for use in water, wastewater, construction, dewatering, industrial, petroleum, original equipment, agriculture, fire protection, heating, ventilating & air conditioning, military, and other liquid-handling applications. It operates in one business segment, the manufacture & sale of pumps and pump systems, and generates revenue from the same. Geographically, it generates the majority of its revenue from the United States.

Share on Social Networks: